We are live on ! Find out more
MCRB icon

Seres Therapeutics

69 hedge funds and large institutions have $52.5M invested in Seres Therapeutics in 2024 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 18 increasing their positions, 18 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

860% more call options, than puts

Call options by funds: $2.75M | Put options by funds: $287K

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

0% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 18

0.24% less ownership

Funds ownership: 2.08%1.85% (-0.24%)

10% less funds holding

Funds holding: 7769 (-8)

13% less capital invested

Capital invested by funds: $60.1M → $52.5M (-$7.59M)

47% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 17

Holders
69
Holders Change
-8
Holders Change %
-10.39%
% of All Funds
0.91%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.01%
New
9
Increased
18
Reduced
18
Closed
17
Calls
$2.75M
Puts
$287K
Net Calls
+$2.47M
Net Calls Change
+$1.87M

MCRB Hedge Fund Activity: Q4 2024 in Review

69 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Seres Therapeutics (MCRB) for Q4 2024, worth a combined $52.5M — down 13% from $60.1M a quarter earlier.

Sellers outnumbered buyers: 17 funds closed out of MCRB and 9 opened new positions — a net loss of 8 holders — while 18 trimmed existing stakes and 18 added.

The largest buyer was Morgan Stanley, adding an estimated $984K. The largest seller was Fidelity Investments, cutting an estimated $850K.

  • 69 institutional investors held Seres Therapeutics (MCRB) as of Q4 2024, down from 77 in Q3 2024.
  • Funds reported $52.5M of Seres Therapeutics stock for Q4 2024, down 13% quarter-over-quarter.
  • 9 funds opened new Seres Therapeutics positions in Q4 2024 and 17 closed out, a net change of -8 holders.
  • The largest Seres Therapeutics buyer in Q4 2024 was Morgan Stanley, an estimated $984K added.
  • The largest Seres Therapeutics seller in Q4 2024 was Fidelity Investments, an estimated $850K sold.

Based on aggregated 13F filings for Q4 2024.